Supply Chain Resilience in Electrochemical Strip Manufacturing

Supply Chain Resilience in Electrochemical Strip Manufacturing

Introduction

Test strips are harder to keep in supply than most electronics, for two reasons. Every strip carries a biological enzyme whose shelf life depends on storage temperature and humidity [2]. And every strip design is cleared by the FDA together with its reagents, so changing a key material can mean going back to the agency [1].

Challenges

• The enzyme is the fragile part. Strips use either glucose oxidase (GOx) or glucose dehydrogenase (GDH); Roche's Accu-Chek Guide strips, for example, use an FAD-dependent GDH [2]. Cold storage is an upstream concern for the purified enzyme before it is applied to strips. Finished strips are a different matter: FDA's review of the Accu-Chek Guide accepted up to 18 months of stability at 39-86°F (4-30°C), and the labeling tells users not to freeze them [2].
• The electrodes are thin films printed from conductive pastes, with the enzyme and an electron mediator (a chemical that shuttles electrons from the enzyme to the electrode) fixed onto the working electrode [3]. The specialized conductive inks used for those electrodes, typically gold, silver or carbon, affect sensor accuracy. We compare the materials in Electrode Material Composition (Carbon vs. Gold/Palladium).

Risks

• White-label manufacturing means one company builds meters and strips that another company sells under its own name. Taiwan is a major base for this work. As of October 2026, FDA's 510(k) database lists 32 glucose-meter clearances for Apex BioTechnology (ApexBio) of Hsinchu and 21 for Bionime of Taichung [4][5][6][7]. A single 2018 Bionime clearance covers meters sold under its own Rightest name and under a GE name [7].
• Taiwan isn't the only source. i-SENS of Seoul, South Korea, holds the FDA clearance for the ReliOn Premier Classic meter [8]. Sinocare of Changsha, China, holds it for the TRUEness and TRUEness Air meters [9] that Trividia Health sells [10]. We found no published market-share figures that would show any one country to be a single point of failure.
• The clearest 2026 example of concentration risk came from one maker rather than one country. On April 28, 2026, FDA recommended that all TRUE METRIX users, including people with co-branded meters sold under store or partner names, move to another way of testing their blood glucose when possible; the recall concerns a software design problem with the meter's E-5 error code [11]. Which meter to move to is a decision for each reader and their care team.
• FDA clearance ties a strip to its materials, though less tightly than "lock-in" suggests. FDA's guidance on device changes says a change in detection reagents or critical reaction components likely requires a new 510(k) [1]. Here's what surprised us: the same guidance lists a new vendor for the same reagent, or a new lot of the same enzyme, as changes that do not ordinarily alter the operating principle of an in vitro diagnostic device [1]. The rule bites hardest when a shortage forces a different material, not just a different supplier.

Resilience Strategies

• Vertical integration, where a strip maker produces key inputs such as enzymes or electrode materials itself, reduces dependence on external suppliers.
• Laser ablation manufacturing minimizes reliance on screen-printing pastes, whose properties can vary from batch to batch. Our article on Manufacturing: Screen Printing vs. Laser Ablation covers both methods.

Conclusion

The 2026 True Metrix recall shows what a single-maker failure looks like from the user's side: one software design issue reached every co-branded store meter built on the same system [11]. More enzyme suppliers or in-house ink production would not have prevented it. Spreading production protects against a material shortage, but a design flaw shared across brands travels with the product.